BiotechTube
Pronoxis

Pronoxis

Stockholm, Sweden· Est.
pronoxis.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

ProNoxis is a preclinical-stage biotech company pioneering a novel therapeutic approach by developing small-molecule agonists of the FPR1/NOX2 pathway to harness the body's natural immune mechanisms for resolving inflammation and fighting infections. The company's lead assets are highly potent, selective FPR1 agonists with proof-of-concept data in relevant disease models. Following a recent corporate restructuring, its core preclinical project and IP were transferred to spin-off Inicure AB in 2024, with ProNoxis continuing to support the program's advancement through grant funding and partnerships.

Inflammatory DiseasesAutoimmune DiseasesInfectious Diseases

Technology Platform

Platform for developing selective, biased small-molecule agonists of the Formyl Peptide Receptor 1 (FPR1) to activate the NADPH oxidase 2 (NOX2) complex, aiming to harness natural immune mechanisms to resolve inflammation and fight infection.

Opportunities

The novel mechanism of activating immune resolution addresses large, underserved markets in chronic inflammation and autoimmunity.
The platform's extension into infectious diseases, particularly in the era of antimicrobial resistance, presents a significant secondary opportunity.
Success in preclinical validation could attract lucrative partnerships with larger pharmaceutical companies seeking innovative immunology assets.

Risk Factors

High scientific risk associated with a novel, contrarian mechanism of activating the NOX2 complex, which must prove safe and effective in humans.
The company is at an early, pre-revenue stage and is dependent on grant funding and future partnerships, creating financial and operational uncertainty.
Recent corporate restructuring and asset transfer to Inicure AB introduce strategic ambiguity regarding ProNoxis's ongoing role and resource allocation.

Competitive Landscape

The competitive landscape for FPR modulators is active, as noted in the company's cited patent review, with several academic and industrial groups exploring both agonists and antagonists for various indications. ProNoxis differentiates itself by focusing on highly potent, selective, and biased FPR1 agonists for NOX2 activation, a niche within the broader field. It faces competition from both other small biotechs and large pharmaceutical companies with extensive immunology pipelines and resources.

More companies in Sweden →